Table 2
Increased cardiac troponins in patients with positive natriuretic peptides: results of the meta-analysis
| Outcome | No of studies | References | Proportion of events (95% CI) | Pooled OR (95% CI) | Homogeneity | |
| p value | I2 (%) | |||||
| All-cause mortality | 6 | 15, 19, 28, 32, 33, 35 | (+): 37/97, 38.1% (28.4% to 47.9%) | 8.0 (3.0 to 21.4) | 0.72 | 0.0 |
| (−): 7/119, 5.9% (1.7% to 10.1%) | ||||||
| APE-related mortality | 4 | 15, 28, 33, 35 | (+): 13/74, 17.6% (8.8% to 26.3%) | 8.6 (2.2 to 34.1) | 0.57 | 0.0 |
| (−): 2/79, 2.5% (0.0% to 5.9%) | ||||||
| Serious adverse outcome | 4 | 15, 19, 28, 32 | (+): 27/79, 34.2% (23.7% to 44.7%) | 13.3 (2.4 to 74.2) | 0.83 | 0.0 |
| (−): 8/49, 16.3% (5.8% to 26.8%) | ||||||
| Right ventricular dysfunction | 2 | 15, 28 | (+): 44/50, 88.0% (78.9% to 97.1%) | 1.67 (0.4 to 6.6) | NA | NA |
| (−): 12/17, 70.6% (50.8% to 90.3%) | ||||||
-
APE, acute pulmonary embolism; CI, confidence interval; NA, not applicable; OR, odds ratio.
-
(+) indicates the proportion of patients with the outcome of interest among those with both positive troponins and natriuretic peptides; (−) indicates the proportion of patients with the outcome of interest among those with negative troponins and positive natriuretic peptides.
